$SERVOTECH

The One Concern: Full-year consolidated revenue was flat at ₹675 crore (vs ₹676 crore in FY25). Why? Because they deliberately shut down the low-margin medical equipment subsidiary (Rebreathe Medical Devices). Excluding that, core business grew ~12%. This is actually a SMART move — cut the bad business, grow the good one. Verdict: GOOD result. Strong YoY growth, expanding margins, highest-ever EBITDA margins, and smart business restructuring. The only weak spot is flat consolidated annual revenue due to a deliberate subsidiary scale-down — which is a management decision, not a red flag. If you're tracking this stock, this is a company firing on most cylinders in a hot sector.